Abstract:Transcription factors (TFs) specifically bind to DNA, recruit cofactor proteins and modulate target gene expression, rendering them essential roles in the regulation of numerous biological processes. Meanwhile, mutated or dysregulated TFs are involved in a variety of human diseases. As multiple signaling pathways ultimately converge at TFs, targeting these TFs directly may prove to be more specific and cause fewer side effects, than targeting the upfront conventional targets in these pathways. All these features together endue TFs with great potential and high selectivity as therapeutic drug targets. However, TFs have been historically considered "undruggable", mainly due to their lack of structural information, especially about the appropriate ligand-binding sites and protein-protein interactions, leading to relatively limited choices in the TF-targeting drug design. In this review, we summarize the recent progress of TF-targeting drugs and highlight certain strategies used for targeting TFs, with a number of representative drugs that have been approved or in the clinical trials as examples. Various approaches in targeting TFs directly or indirectly have been developed. Common direct strategies include aiming at defined binding pockets, proteolysis-targeting chimaera (PROTAC), and mutant protein reactivation. In contrast, the indirect ones comprise inhibition of protein-protein interactions between TF and other proteins, blockade of TF expression, targeting the post-translational modifications, and targeting the TF-DNA interactions. With more comprehensive structural information about TFs revealed by the powerful cryo-electron microscopy technology and predicted by machine-learning algorithms, plus more efficient compound screening platforms and a deeper understanding of TF-disease relationships, the development of TF-targeting drugs will certainly be accelerated in the near future.

Targeted Degradation of Transcription Factors by TRAFTACs: Transcription Factor Targeting Chimeras

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

TF-PROTACs Enable Targeted Degradation of Transcription Factors.

Targeting Undruggable Transcription Factors with PROTACs: Advances and Perspectives

Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG

Targeting transcription factors in cancer — from undruggable to reality

PROTACs: New method to degrade transcription regulating proteins

ZIF-90-loaded DNAzyme-responsive PROTAC for the Self-Powered Degradation of NF-κB

Transferrin receptor targeting chimeras for membrane protein degradation

Destruction of DNA-binding proteins by programmable O’PROTAC: Oligonucleotide-based PROTAC

Destruction of DNA-Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG (Adv. Sci. 20/2021)

Current Strategies and Progress for Targeting the “undruggable” Transcription Factors

Telomere Targeting Chimera Enables Targeted Destruction of Telomeric Repeat-Binding Factor Proteins.

ARE-PROTACs Enable Co-degradation of an Nrf2-MafG Heterodimer.

Selective Proteolysis of Activated Transcriptional Factor by NIR‐Responsive Palindromic DNA Thalidomide Conjugate Inhibits the Canonical Smad Pathway

DNA framework-engineered chimeras platform enables selectively targeted protein degradation

Protocol for constructing tumor-targeting ANM-PROTACs for degradation of transcription factors

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future

Bridging the gap in protein targeting

TF-DUBTACs Stabilize Tumor Suppressor Transcription Factors.